Lexaria Bioscience Corp. LEXX Archives - Page 23 of 39

FridaySep 02, 2022 10:54 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Appoints New Board Member

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has announced an addition to its board of directors; the company named industry veteran Catherine Turkel, PharmD, PhD, as the newest member of its board. Turkel brings more than two decades of experience as an executive-level leader in both start-up and mid-size pharma/biotech companies. As founder and CEO of Nezee Therapeutics, she gained critical expertise and insight in the space; she also served as president and head of research and development Novus Therapeutics, which was later renamed Eledon Pharmaceuticals Inc. (NASDAQ: ELDN). Currently she serves as an independent board director…

WednesdayAug 31, 2022 2:21 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces New Patent in Mexico

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, is continuing to accumulate international patents; most recently the company received its 27th patent granted worldwide. Part of Lexaria’s third patent family — Stable Ready-to-Drink Beverage Compositions Comprising Lipophilic Active Agents, from which patents have already been granted from Australia, India and Japan — the newest patent comes from Mexico and applies to range of active ingredients including non-psychoactive cannabinoids and NSAIDs. The announcement noted that types of products covered by the patent include specific pharmaceutical product formats along with an array of ready-to-drink consumer retail beverage products. According to the announcement,…

TuesdayAug 30, 2022 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces the Availability of a Broadcast titled, “The Power of Science to Stop a Killer”

Lexaria’s latest broadcast highlights the company’s progress in finding a potential solution for hypertension treatment while also pointing out why such a solution is much needed at this point Since the company began developing its patented DehydraTECH(TM) technology in 2014, it has made significant progress in its clinical studies, even as it currently focuses on human clinical research to evaluate the tolerability, safety, and efficacy of its solution for hypertension treatment Lexaria expressed its confidence in its proposed solution, noting that it will not only be a safer but also better-tolerated drug candidate, unlike current alternatives in the market whose…

FridayAug 26, 2022 11:15 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Drug Development Program and Recent FDA Confirmation Position It for Favorable Valuation

Lexaria is a global innovator of drug delivery platforms, including its patented DehydraTECH(TM) technology The company recently released information that would help its stakeholders research and understand how biotech and pharmaceutical companies are valued Based on some of the methodologies used in valuation, Lexaria is positioned favorably as its DehydraTECH-processed CBD for the treatment of hypertension has successfully reached the IND application stage, with the program recently receiving an additional boost The FDA agreed with Lexaria’s proposal to pursue a 505(b)(2) new drug application (“NDA”) regulatory pathway, an abbreviated pathway, for its hypertension program As a follow-up to recent coverage…

MondayAug 22, 2022 1:14 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Stands to Gain Substantial Revenue Through Licensing of DehydraTECH(TM)

Lexaria Bioscience Corp. (NASDAQ: LEXX) recently announced that Japanese Licensee, Premier Wellness Science Co. Ltd., officially launched the first generation of its new cannabidiol (“CBD”) products under the brand, “Ko.” “The exclusive rights between Premier and Lexaria are subject to two previously issued licenses for using DehydraTECH technology in Japan for non-pharmaceutical cannabinoid products… Under the terms of the license agreement with Lexaria, Premier purchased rights to the company’s DehydraTECH technology for use in the non-pharmaceutical market for CBD and hemp ingredients in oral liquid and non-liquid product form, including topical, hair care, lip care, and cosmetics,” a recent article…

FridayAug 19, 2022 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Delighted About Well-Received DehydraTECH-CBD Proposals by the FDA; Maintains Late 2022/Early 2023 Target For Complete IND Application

Lexaria’s successful HYPER-H21-2 human clinical study, whose results were announced in the first week of September 2021, laid the groundwork for the company’s patented DehydraTECH(TM)-processed CBD NDA Chris Bunka, the company’s CEO, referred to the results as “statistically significant,” ultimately kickstarting the IND application process with the FDA Lexaria has since received a full written positive response from the FDA on its DehydraTECH-CBD, agreeing to the company’s proposal to pursue the 505(b)(2) NDA regulatory pathway As a result of the favorable FDA response, Lexaria expects to remain on track to file its full IND application, 6-9 months sooner than if…

WednesdayAug 17, 2022 2:35 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH Capable of Delivering APIs More Efficiently by Overcoming Food Effect

Lexaria Bioscience Corp. (NASDAQ: LEXX) recently announced the allowance of a new patent in Japan, the fourth to be granted in that country and the 26th worldwide. “Entitled Lipophilic Active Agent Infused Compositions with Reduced Food Effect, this is the first patent issued from Lexaria’s seventh patent family and refers to tetrahydrocannabinol (‘THC’). The new patent acknowledges DehydraTECH(TM)’s ability to deliver active pharmaceutical ingredients (‘APIs’) more efficiently, in a process known as absorption, regardless of the presence of food in the gastrointestinal system. Ordinarily, food impacts drug absorption by physically interacting with drugs, altering the pH, stimulating bile flow, slowing…

TuesdayAug 16, 2022 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Enters Four Partnerships, Boosts ‘Revenue Picture’

Lexaria Bioscience, a global innovator in drug delivery platforms, recently announced partnerships with Premier Wellness Science Co., BevNology, AnodGen Bioceuticals, and Valcon Medical A/S According to coverage by Zacks Small-Cap Research, who value Lexaria at $15 per share, the most impactful of these partnerships is with Premier because the company is expected to start paying license fees in early September In a June 7 Fireside Chat, Lexaria Chair and CEO Chris Bunka disclosed that the company is capitalizing on partnerships with “national players in different areas of the world” to improve its “revenue picture” and offset its cash burn In…

FridayAug 12, 2022 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Inches Closer to DehydraTECH-CBD FDA Evaluation Following Successful Dosing in Multi-Week HYPER-H21-4 Human Clinical Study

Lexaria just completed dosing for its HYPER H21-4 human clinical study that dosed 64 patients aged between 40 and 70 with measured elevated blood pressure, stage 1 and stage 2 hypertension HYPER-H21-4, Lexaria’s most ambitious hypertension clinical study yet, builds on the success of HYPER-H21-1 and HYPER-H21-2, both completed in 2021 It explores the use of the company’s patented DehydraTECH(TM) technology in the potential treatment of hypertension Lexaria is confident that the additional data sets collected over the course of the study will lead to supplementary applications for DehydraTECH while providing valuable additional insights into the long-term health benefits of…

ThursdayAug 11, 2022 12:14 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Discusses Biotech Industry Valuation Metrics

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) is a global innovator in drug delivery platforms. The company today issued information to its stakeholders as an aid to conveniently research and understand various non-affiliated third-party sources and their methodologies for valuing biotech and pharmaceutical companies. “Biotech companies with little to no revenue can still be worth billions,” Raphael Rottgen, CFA, FRM, was quoted in the press release. “While valuations can be extremely low or extremely high, there is often underlying logic in identifying risks and arriving at those valuations. Developing new drugs can have significant costs of over $1 billion and can take…

Site Search

Company Search

Tag: Lexaria Bioscience Corp. LEXX